IMS Health Holdings Inc. (NYSE:IMS) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research note issued to investors on Wednesday. The firm presently has a $34.00 target price on the stock. Zacks Investment Research’s target price suggests a potential upside of 11.07% from the company’s current price.
According to Zacks, “IMS Health Holdings, Inc. engages in providing information, services, and technology to the healthcare industry worldwide. The company develops healthcare measurement solutions, such as IMS LifeLink program, IMS NPA Market Dynamics, IMS Xponent Prescribing Dynamics, IMS PlanTrak Market Dynamics, and Specialty Market Dynamics. It serves pharmaceutical, payers, government, providers, pharmacies, consumer health, pharmaceutical distribution, and financial community sectors. The company also provides consumer health insights, forecasting solutions, payer insights, pharmaceutical measurement solutions, and publications. IMS Health Holdings, Inc. is based in Danbury, Connecticut. “
Separately, TheStreet upgraded shares of IMS Health Holdings from a “hold” rating to a “buy” rating in a research report on Wednesday, July 20th. Three research analysts have rated the stock with a hold rating and six have issued a buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus price target of $31.00.
Shares of IMS Health Holdings (NYSE:IMS) opened at 30.61 on Wednesday. IMS Health Holdings has a 52 week low of $22.36 and a 52 week high of $31.59. The firm has a 50-day moving average of $29.69 and a 200 day moving average of $27.23. The company has a market cap of $10.08 billion, a P/E ratio of 74.30 and a beta of 0.85.
IMS Health Holdings (NYSE:IMS) last issued its quarterly earnings data on Wednesday, July 27th. The company reported $0.41 earnings per share for the quarter, topping analysts’ consensus estimates of $0.38 by $0.03. The business earned $802 million during the quarter, compared to the consensus estimate of $796.93 million. IMS Health Holdings had a net margin of 4.45% and a return on equity of 30.61%. The company’s revenue was up 112.4% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.37 earnings per share. Equities analysts expect that IMS Health Holdings will post $1.64 EPS for the current fiscal year.
Hedge funds have recently added to or reduced their stakes in the company. Fjarde AP Fonden Fourth Swedish National Pension Fund boosted its stake in shares of IMS Health Holdings by 8.5% in the first quarter. Fjarde AP Fonden Fourth Swedish National Pension Fund now owns 50,768 shares of the company’s stock valued at $1,348,000 after buying an additional 3,962 shares in the last quarter. Pacad Investment Ltd. boosted its stake in shares of IMS Health Holdings by 9.3% in the first quarter. Pacad Investment Ltd. now owns 11,700 shares of the company’s stock valued at $311,000 after buying an additional 1,000 shares in the last quarter. Ngam Advisors L.P. boosted its stake in shares of IMS Health Holdings by 384.9% in the first quarter. Ngam Advisors L.P. now owns 258,072 shares of the company’s stock valued at $6,852,000 after buying an additional 204,854 shares in the last quarter. RMB Capital Management LLC acquired a new stake in shares of IMS Health Holdings during the first quarter valued at about $261,000. Finally, BlackRock Inc. boosted its stake in shares of IMS Health Holdings by 6.9% in the first quarter. BlackRock Inc. now owns 112,261 shares of the company’s stock valued at $2,981,000 after buying an additional 7,251 shares in the last quarter. 90.25% of the stock is owned by institutional investors and hedge funds.
About IMS Health Holdings
IMS Health Holdings, Inc (IMS) is an information and technology services company that provides solutions to its clients in the healthcare industry. The Company has its presence in over 100 countries. The Company’s data set contains over 10 petabytes of data and over 500 million patient records. It serves healthcare organizations and life science companies, including pharmaceutical, biotechnology, consumer health and medical device manufacturers, as well as distributors, providers, payers, government agencies, policymakers, researchers and the financial community.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for IMS Health Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IMS Health Holdings Inc. and related companies with MarketBeat.com's FREE daily email newsletter.